Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

  1. Castellano, D. 1
  2. Capdevila, J. 2
  3. Sastre, J. 3
  4. Alonso, V. 4
  5. Llanos, M. 5
  6. García-Carbonero, R. 6
  7. Manzano Mozo, J.L. 7
  8. Sevilla, I. 8
  9. Durán, I. 9
  10. Salazar, R. 10
  1. 1 Hospital Universtiario 12 de Octubre
  2. 2 Hospital Vall d'Hebron
    info

    Hospital Vall d'Hebron

    Barcelona, España

    ROR https://ror.org/03ba28x55

  3. 3 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  4. 4 Hospital Miguel Servet
    info

    Hospital Miguel Servet

    Zaragoza, España

    ROR https://ror.org/01r13mt55

  5. 5 Hospital Universitario de Canarias
    info

    Hospital Universitario de Canarias

    San Cristóbal de La Laguna, España

    ROR https://ror.org/05qndj312

  6. 6 Hospital Universitario Virgen del Rocío
    info

    Hospital Universitario Virgen del Rocío

    Sevilla, España

    ROR https://ror.org/04vfhnm78

  7. 7 Hospital Universitari Germans Trias i Pujol
    info

    Hospital Universitari Germans Trias i Pujol

    Barcelona, España

    ROR https://ror.org/04wxdxa47

  8. 8 Hospital Universitario Virgen de la Victoria
    info

    Hospital Universitario Virgen de la Victoria

    Málaga, España

    ROR https://ror.org/05xxs2z38

  9. 9 Hospital Madrid-Norte Sanchinarro
  10. 10 Institute Catalá Oncología
    info

    Institute Catalá Oncología

    Barcelona, España

    ROR https://ror.org/01j1eb875

Journal:
European Journal of Cancer

ISSN: 0959-8049

Year of publication: 2013

Volume: 49

Issue: 18

Pages: 3780-3787

Type: Article

DOI: 10.1016/j.ejca.2013.06.042 PMID: 24012098 SCOPUS: 2-s2.0-84888009143 GOOGLE SCHOLAR
Data source: Scopus